Publications (2)2.64 Total impact
-
Article: Identification of beta2-microglobulin as a potential target for ovarian cancer.
[show abstract] [hide abstract]
ABSTRACT: Ovarian cancer is one of the most lethal gynecological cancers. Antibody-based therapy has emerged as an important therapeutic approach for an increasing number of malignancies. Here, we prepared an antibody pool against SKOV3 ovarian cancer cells, which could induce apoptosis of SKOV3 cells in a dose- and time-dependent manner. Through SEREX analysis, beta 2-microglobulin (b2M) was identified as the potential target molecules of functional antibodies. The immune IgG (i-IgG) of antibody pool had little effects on other kinds of cancer cells, maybe because of the more secretion of b2M by SKOV3. Further studies indicated that specific antibody of b2M indeed also can inhibit the growth of SKOV3. In addition, overexpression of b2M could promote the growth of SKOV3 cells in vitro, by colony formation and anchorage-independent growth assay, at least partially through the activation of PI3K/Akt pathway. Thus, b2M could be a potential therapeutic target in ovarian cancer.Cancer biology & therapy 12/2009; 8(24):2323-8. · 2.64 Impact Factor -
Article: [Serological screening of xenogeneic antigens from rat testis].
[show abstract] [hide abstract]
ABSTRACT: It is the intent of this study to analyzed the rat testis library by employing a modified SEREX (serological analysis of recombinant cDNA expression library) approach to find the xenogeneic homologous tumor antigens which could be useful in developing cancer vaccines. The screening serum was obtained from the immunized rabbits with human ovarian cancer cells, and 10 positive clones were isolated from the rat testis cDNA library using SEREX technology. We found these 10 clones encoded seven different proteins by means of bioinformatic analysis. Among them, OV-2 and OV-4 encode proteins related to carcinoma in human, yet OV-6 and OV-7 are novel and their encoded proteins remain unknown. This study indicates that the utilization of xenogeneic immunized serum in the serological screening of xenogeneic homologous tumor antigens may expand the application of traditional SEREX technology.Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 06/2004; 35(3):305-8.
